factor TFF2 is a member of a tripartite family of small proteins that is produced by the stomach and the colon. Recombinant TFF2, when applied intrarectally in a rodent model of hapten colitis, hastens mucosal healing and reduces inflammatory indexes. Additionally, TFF2 is expressed in immune organs, supporting a potential immunomodulatory and reparative role in the bowel. In this study we confirm that TFF2 is expressed in the colon and is specifically enriched in epithelial cells relative to colonic leukocytes. TFF2-deficient, but not TFF1-deficient, mice exhibit a more severe response to acute or chronic dextran sulfate (DSS)-induced colitis that correlates with a 50% loss of expression of TFF3, the principal colonic trefoil. In addition, the response to acute colitis is associated with altered expression of IL-6 and IL-33, but not other inflammatory cytokines. While TFF2 can reduce macrophage responsiveness and block inflammatory cell recruitment to the colon, the major role in limiting the susceptibility to acute colitis appears to be maintenance of barrier function. Bone marrow transfer experiments demonstrate that leukocyte expression of TFF2 is not sufficient for prevention of colitis induction but, rather, that the gastrointestinal epithelium is the primary source of TFF2. Together, these findings illustrate that epithelial TFF2 is an important endogenous regulator of gut mucosal homeostasis that can modulate immune and epithelial compartments. Because of its extreme stability, even in the corrosive gut lumen, TFF2 is an attractive candidate as an oral therapeutic scaffold for future drug development in the treatment of inflammatory bowel disease. mucosal immunity; trefoil; trefoil factor 2; IL-33; colitis; dextran sodium sulfate TREFOIL FACTORS (TFFs) constitute a three-member family of small, secreted peptides with a unique disulfide-bound tripartite structure. TFF1 and TFF2 have been shown to be expressed primarily in the stomach and TFF1 and TFF3 in the intestine and colon (15, 20, 23, 38, 49, 52) . The three TFF genes are present together on a short region of chromosome 21 in humans (and on mouse chromosome 17), and, given the overlapping distribution of their derived proteins, it is not surprising that they have common regulatory elements and crossregulatory roles. For instance, genetic depletion of TFF2 can induce TFF1 expression in the thymus, can inhibit TFF expression in the spleen, and is without effect in the stomach (23), and its effect in the colon has not been determined, while application of TFF2 to stomach cells increases transcription of TFF2 in a MAPK-dependent fashion (5). TFF3, the main colonic TFF and a major epithelial homeostatic regulator and repair factor, is negatively regulated by proinflammatory colitis-associated cytokines (8), although cross-regulation of TFF3 by the other TFFs is yet to be determined.
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More recently, the expression pattern of the TFFs has expanded to incorporate other mucosal sites, including the lung (29, 56) , breast (18, 37, 42) , and eye (24) , with expression at many of these sites ectopically induced following induction of inflammatory pathology or tissue damage. In the gut, ectopic expression of TFF2, in particular, occurs in human Crohn's disease (25) and in gastric intestinal metaplasia (20) . In addition, TFF2 and other TFFs have been detected at low levels in rodent lymphoid tissues, including the spleen (7, 23) and thymus (7) , and in extracts from peritoneal macrophages (13, 23) , suggesting a potential immunomodulatory role.
Coincident with the site of expression of the TFFs, is their main purported role, which is the protection and restitutive repair of mucosal surfaces at which they are secreted (10, 16, 32, 54, 57) . TFFs primarily mediate these roles by promoting motogenesis (4, 16) , enhancing differentiation (12, 19, 27, 46) , and inhibiting inflammation throughout the gut (13, 23, 34) . TFFs are secreted luminally but are also secreted into the circulation and, thus, appear to act systemically as well (53) . We showed that TFF2, when applied intrarectally in a rat model of hapten colitis, accelerates mucosal healing and reduces inflammatory indexes (51) . Similar protective effects of TFF2 have been demonstrated in dextran sodium sulfate (DSS)-induced colitis in the mouse (36) , likely mediated in part by reduced leukocyte recruitment coincident with inhibition of endothelial VCAM1 expression (43) . An additional target of TFF2 in the inflammatory cascade appears to be macrophage-derived nitric oxide (NO). TFF2 can inhibit inducible NO synthase to reduce proinflammatory NO and the production of free radicals (13) . Together, these findings suggest that TFF2 is required for maintenance of mucosal integrity throughout the gut and that reduced TFF2 expression increases susceptibility to inflammatory disease in the colon in particular.
The potent actions of exogenous TFF2 in the upper and lower gut imply a direct role for TFF2 in preventing colitis induction and highlight the likely importance of TFF2 expression in the epithelial and immunocyte compartments in this regard. With these questions in mind, the focus of the present study was twofold: 1) to investigate the pathogenic outcomes of DSS-induced colitis, including mechanisms of susceptibil-ity, especially downstream epithelial and immune gene targets of TFF2, in wild-type or TFF2-deficient mice, and 2) to determine whether mucosal or infiltrating immunocyte-derived TFF2 is more important in mediating the anti-inflammatory and repair functions of this TFF.
MATERIALS AND METHODS
Mice. TFF1-and TFF2-deficient mice were developed as previously described (11, 50) . All mice were backcrossed for a minimum of eight generations onto a C57BL/6 background, and age-matched wild-type littermates were used as controls. Mice were housed in a 
CD45+
specific pathogen-free (SPF) animal facility. Mice were genotyped by multiplex PCR, as previously described (34) . For all mouse experiments, equivalent numbers of males and females were used in the wild-type and deficient groups, and the values for genders were averaged. All animal experiments were performed with the approval of the Murdoch Children's Research Institute Animal Ethics Committee (AEC A713). Induction of DSS colitis. Acute and chronic models of DSS-induced colitis were used. Because the standard acute DSS protocol was lethal in TFF2-deficient mice, it was modified as follows. On days 1-5, 3% DSS (mol wt ϳ40,000; TdB Consultancy) in drinking water was provided ad libitum for TFF1-deficient, TFF2-deficient, and matched wild-type mice, and plain drinking water was provided for controls. On days 6 -8, standard drinking water was provided for all mice, and mice were culled on day 8. In the chronic DSS protocol, on days 1-5, 3% DSS in drinking water was provided ad libitum for TFF2-deficient and matched wild-type mice, and plain drinking water was provided for controls. On days 6 -12, standard drinking water was provided for all mice. This protocol was repeated four times, with mice culled on day 44. All mice were weighed daily.
Macroscopic and histological assessment. Colons were removed from mice from the cecum to the rectum and photographed with a Coolpix 4500 digital camera (Nikon Instruments, Melville, NY). Length of the colon was measured from the images using ImageJ software for Windows version 1.3 (http://rsb.info.nih.gov/ij/index.html). Subsequently, the colon was cut open and bisected longitudinally; half was frozen in liquid nitrogen, and the other half was fixed in 4% buffered paraformaldehyde before processing. Paraffin sections (4 m) were stained with hematoxylin-eosin.
Microscopic morphometry. Images were captured with a Coolpix 4500 digital camera, and morphometric analysis was performed using ImageJ software for Windows version 1.3. For damage measurements, images of the entire colonic mucosa were captured, and a digital line was drawn along the muscularis mucosa in all regions where the epithelium was no longer intact (termed damaged), and the software was used to quantify this. The length of the damaged mucosa was expressed relative to the total length of the mucosa.
Analysis of leukocyte infiltration into the colon. Single cell suspensions were isolated from the colon as previously reported (55) . Briefly, colons were incubated with shaking in Hanks' balanced saline solution (HBSS) containing 5 mM EDTA and 1 mM DTT. The resultant cell solution contained epithelial cells and intraepithelial leukocytes (IELs). The remnant tissue was rinsed in HBSS to remove EDTA and DTT and digested with shaking in HBSS containing 0.4 mg/ml collagenase type IV. The resultant cell suspension contained lamina propria mononuclear cells (LPMCs). IELS and LPMCs were purified from contaminating epithelium, stroma, and dead cells by centrifugation on a 40%-80% Percoll gradient. Purified IELs and LPMCs were stained with a cocktail of leukocyte cell surface markers [CD4 (catalog no. 560468), CD8a (catalog no. 561967), CD11b (catalog no. 57397), CD11c (catalog no. 550261), CD45R (catalog no. 553087), and Gr-1 (catalog no. 552093); all from BD Biosciences]. CountBright beads were used to determine total cell number per sample, and cell surface staining was analyzed on a flow cytometer (model LSR II, BD Biosciences) using FACSDiva (BD Biosciences). On the basis of forward-and sidescatter, propidium iodide staining, and staining on unutilized wavelengths, the following cell populations were eliminated: dead cells, aggregates, debris, red blood cells, and autofluorescent cells.
Isolation of purified colonic cell populations. LPMCs were prepared as described above and stained for CD45 (catalog no. 561487, BD Biosciences) and E-cadherin (catalog no. FAB7481P, R & D Systems). On the basis of forward-and sidescatter, propidium iodide staining, and staining on unutilized wavelengths, the following cell populations were eliminated: dead cells, aggregates, debris, red blood cells, and autofluorescent cells. Leukocytes (CD45 ϩ E-cadherin Ϫ ) and epithelial cells (CD45 Ϫ E-cadherin ϩ ) were isolated from the remaining cells on an Influx sorter (BD Biosciences) on a 100-m nozzle at 22 psi.
Bone marrow transplants. Bone marrow was prepared from male TFF2-deficient or wild-type mice as follows. Mice were culled, femurs were removed, and bone marrow was flushed with HBSS and a 20-gauge needle, strained to a single cell suspension, counted, and stored on ice for injection into recipient mice. Bone marrow chimeras were generated as described elsewhere (44) . Briefly, recipient female TFF2-deficient mice were lethally irradiated (2 doses, 5.5 Gy, 3 h apart) and reconstituted with 5 ϫ 10 6 donor cells by tail vein injection. Recipient mice were treated with prophylactic antibiotics (2 mg/ml neomycin sulfate; Sigma) for 4 wk to allow for complete reconstitution. Mice were then challenged with the acute DSS protocol as described above.
Isolation of peritoneal macrophages. Peritoneal macrophages were recovered from mice after injection of 5 ml of HBSS into the peritoneal cavity. To enrich for macrophages, cells were resuspended in RPMI with 10% FCS and plated onto uncoated plastic. After a 10-min incubation, nonadherent cells were removed and plated onto six-well dishes. Adherent macrophage-enriched cells were incubated for 16 h in 10% FCS, stimulated with LPS (100 ng/ml), and harvested 3 h later. RNA was purified using the RNeasy Minikit (Qiagen).
Analysis of mRNA expression. Total RNA was harvested using TRIzol reagent (Life Technologies) or RNeasy columns (catalog no. 74104, Qiagen). RNA (3 g, n Ն 5 animals/group) was reversetranscribed into cDNA using Moloney's murine leukemia virus reverse transcriptase (Promega) primed with oligo(dT). Primer Express (Applied Biosystems) was used to design quantitative RT-PCR (qRT-PCR) primers: IL-1␤ (CAGGCAGTATCACTCATTGTGG and GTGCAGTT-GTCTAATGGGAACG), myeloperoxidase (MPO; CGGCGCATGTG-CAGTTAATA and TGTAGCCGTGAGGATGATAAAGC), IL-19 (TAAGGAGAATCAGCAGCATTGC and CACCTGACATCGCTC-CAGAGA), IL-10 (TGATGCCCCAGGCAGAGA and CAC-CCAGGGAATTCAAATGC), IL-6 (AAGAACGATAGTCAATTC-CAGAAACC and AAGAAGGCAACTGGATGGAAGTC), wild-type TFF2 (TATCAGAAGCCAGCCTTACACC and CTGTGGTTTTT-GACCTGAGAGC), and mutant TFF2 (TATCAGAAGCCAGCCTTA-CACC and TAGCCTGAAGAACGAGATCAGC). SYBR Green chemistry was used with rL32 as the internal reference gene. qRT-PCR conditions were 95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 15 s (AB7500, Applied Biosystems). Results were analyzed using sequence detector software, and relative fold differences were determined using the cycle threshold (Ϫ2⌬⌬CT) method.
Statistical analysis. Values are means Ϯ SE. Statistical analysis was performed using one-way analysis of variance and the appropriate parametric or nonparametric statistical test using Sigmastat (Jandel Scientific, San Rafael, CA). P Յ 0.05 was considered statistically significant. Fig. 2 . A: colons were isolated from wild-type mice (n ϭ 2), and a single cell suspension was prepared and stained with CD45 and E-cadherin. Leukocytes (CD45 ϩ E-cadherin Ϫ ) and epithelial cells (CD45 Ϫ E-cadherin ϩ ) were isolated from these preparations. Unstained cells did not receive any antibody and demonstrate the background staining present in these cell preparations. RNA was extracted from the sorted cell populations and subjected to qRT-PCR analysis of TFF2, CD4, CD8, epcam, cytokeratin 18, and the housekeeping gene L32. Results are expressed as fold change compared with unsorted single cell preparations. Bars show mean values; n ϭ 5/group. B: wild-type mice were housed in specific pathogen-free (SPF) or conventional facilities. RNA was extracted from spleens of mice and subjected to qRT-PCR analysis. iNOS, inducible nitric oxide synthase. Values are means Ϯ SE. 
RESULTS
Expression of TFF peptides in the colon is cross-regulated. mRNA was prepared from the colon, spleen, and thymus of wild-type and TFF2-deficient mice that had been housed in SPF microisolators and analyzed for expression of TFF1, TFF2, and TFF3 ( Fig. 1 ; n ϭ 5/genotype with data from 2 representative animals shown). TFF1 was expressed at low levels in the colon and spleen and at a significantly higher level in the thymus. Intriguingly, TFF2 genetic deficiency led to an increase in TFF1 expression in the spleen but a decrease in the colon and thymus (Fig. 1A) . TFF2 was expressed in the colon and thymus of wild-type mice but, under these housing circumstances, was not detectable in the spleen. TFF2-deficient mice did not express TFF2, as we expected. TFF3 was expressed in the colon, spleen, and thymus of wild-type mice. Interestingly, expression of TFF3 was modulated by knockout of the TFF2 gene, such that, in its absence, TFF3 expression was decreased in the colon and increased in the spleen and thymus (Fig. 1A) . We confirmed by qRT-PCR that TFF1 expression was decreased in the colon of TFF2-deficient mice (2.97 Ϯ 0.56 fold in TFF2-deficient relative to wild-type mice) and TFF3 mRNA expression was also decreased in the colon of TFF2-deficient mice (1.78 Ϯ 0.15 fold in TFF2-deficient relative to wild-type mice) and increased in the spleen (30.14 Ϯ 3.46 fold in TFF2-deficient relative to wild-type mice) and thymus (7.74 Ϯ 0.85 fold in TFF2-deficient relative to wildtype mice; Fig. 1A ).
Acute DSS colitis was induced in wild-type mice, and expression of the TFF family members was analyzed by qRT-PCR. Expression of all three TFFs was decreased in the colons of mice with DSS-induced colitis compared with watertreated controls ( Fig. 1B; Ϫ2 .56 Ϯ 0.71, Ϫ195.67 Ϯ 79.72, and Ϫ4.39 Ϯ 1.00 fold for TFF1, TFF2, and TFF3, respectively), with expression of TFF2, in particular, most profoundly decreased. As DSS-induced colitis is an inflammatory condition, reduced TFF expression in colitic colons suggests that the TFFs are not expressed by infiltrating inflammatory cells.
To clarify whether colonic epithelial cells or leukocytes express TFF2, a single cell suspension of the colon was prepared, and the cells were sorted on the basis of CD45 (leukocyte) or E-cadherin (epithelial) expression (Fig. 2A) . The CD45 ϩ population additionally expressed the leukocyte markers CD4 and CD8 and exhibited negligible expression of the epithelial markers epcam and cytokeratin 18. In contrast, the E-cadherin ϩ population additionally expressed epcam and cytokeratin 18 and showed negligible expression of CD4 and CD8 ( Fig. 2A) . Expression of TFF2 was quantified in each population and found to be enriched in the E-cadherin ϩ cells and negligible in the CD45 ϩ cells ( Fig. 2A) , providing further evidence that, in the colon, TFF2 is predominantly expressed by epithelial cells, and not by leukocytes.
Since modest TFF2 mRNA expression has previously been detected in rodent spleen (4, 19) , we compared splenic expression of TFF2 in mice housed in SPF or conventional (open-top cage) facilities (Fig. 2B) . As previously reported, TFF2 mRNA was near the lower limit of detection in spleens from animals housed in SPF conditions, but expression was strongly induced in spleens of conventionally housed mice. To better understand the stimulatory conditions of different housing environments, spleens were also analyzed for a range of pro-and antiinflammatory moderators (Fig. 2B) . Notably, the T helper (Th) type 2 (Th2) cell cytokines IL-13 and IL-4, as well as IL-1␤, inducible NO synthase, and IL-10, were significantly upregulated in spleens from conventionally housed wild-type mice, while the Th1 cell cytokines IFN␥ and IL-12 were unchanged. Together, these findings suggest that TFF2 mRNA expression in the spleen is very low basally but can be readily induced when mice are exposed to inflammatory stimuli, particularly those that promote Th2 cell immunity.
TFF1 expression does not influence susceptibility to DSSinduced colitis. Among the TFF family members, TFF1 and TFF2 are predominantly expressed in the stomach, with limited expression in the lower gut ( Fig. 1) (47) . However, TFF2 deficiency has been shown to moderate the response to DSSinduced colitis (23) . Here we demonstrate that this effect is specific to TFF2, since TFF1-deficient and wild-type mice show the same response to acute DSS. Weight loss in TFF1-deficient mice was equivalent to that in wild-type mice (Fig.  3Ai) , as was colon damage (Fig. 3Aii) .
TFF2 protects mice from acute and chronic DSS-induced colitis. As previously reported (23), TFF2-deficient mice are more susceptible to acute DSS-induced colitis, showing more severe weight loss (ϳ5% on days 6 -8) than wild-type mice (Fig. 3Bi) but, interestingly, not greater colon shortening (Fig.  3Bii) or damage (Fig. 3Biii) . Additionally, in regions of the colon from DSS-treated mice that were comparatively unaffected by ulceration, the number and distribution of goblet cells were not affected by the TFF2 null mutation (Fig. 3Biii) . TFF2-deficient mice are also more susceptible to chronic DSS-induced colitis, displaying more weight loss throughout the experiment, including at its completion ( Fig. 3Ci ; 88.0 Ϯ 3.5 vs. 96.9 Ϯ 1.4%), again without greater colon shortening (Fig. 3Cii) . Interestingly, in these longer-term studies, changes in body weight became most apparent beginning on day 10, suggesting a significant time lag in the peak of systemic Fig. 3 . TFF1 deficiency does not alter susceptibility to DSS-induced colitis. A: drinking water containing 3% DSS was provided to TFF1-deficient (n ϭ 5) and wild-type (n ϭ 5) mice from day 1 to day 5. DSS was removed on day 6, and mice were culled on day 8. Control mice received water throughout the protocol. Body weight was measured daily and found to be similarly decreased in DSS-treated wild-type and TFF1-deficient mice but unchanged in controls (i). Upon culling, the colon was removed and divided for histological or mRNA analysis. Wild-type and TFF1-deficient mice had comparable levels of DSS-induced colonic ulceration (ii). *P Յ 0.05 vs. wild-type water-treated mice. B and C: TFF2-deficient mice are more susceptible to acute (B) and chronic (C) DSS-induced colitis. In the acute model, drinking water containing 3% DSS was provided to TFF2-deficient (n ϭ 12) and wild-type (n ϭ 12) mice from day 1 to day 5. DSS was removed on day 6, and mice were culled on day 8. Control mice received water throughout the protocol. TFF2-deficient mice consistently lost more weight following this protocol than their wild-type counterparts (Bi). They did not, however, exhibit a more pronounced shortening of the colon (Bii) or more pronounced DSS-induced colonic ulceration (Biii). In the chronic model, drinking water containing 3% DSS was provided to TFF2-deficient and wild-type mice from day 1 to day 5. DSS was removed on days 6 -12, and this cycle was repeated 4 times. Again, TFF2-deficient mice consistently lost more weight than their wild-type counterparts (Ci). They did not exhibit a more pronounced shortening of the colon (Cii). *P Յ 0.05 vs. wild-type DSS-treated mice or as indicated.
immune activation (Fig. 3Ci) . Therefore, TFF2 expression is able to moderate DSS-induced weight loss, but without moderating DSS-induced mucosal damage.
TFF expression has little effect on inflammatory markers in DSS-induced colitis. As an indication of the inflammatory response in the colon, mRNA expression of a number of colitis-associated cytokines was quantified and found to be equivalent in TFF1-deficient and wild-type mice (Fig. 4A) . Of interest was the finding that basal expression of IL-19 and IL-33 in the water-treated controls was significantly less (each 9-fold) in TFF1-deficient than wild-type mice (Fig. 4A) . This suggests that TFF1 expression moderates the basal inflammatory state of the colon but that these changes do not influence the response to acute DSS-induced colitis.
Expression of colitis-associated cytokine mRNA was also assessed in TFF2-deficient mice in the acute colitis model. IL-6 expression was increased in wild-type mice following acute DSS treatment and was further augmented in the absence of TFF2 ( Fig. 4B ; 236.9 Ϯ 106.9 and 550.0 Ϯ 71.2 fold relative to wild-type). However, expression of other inflammatory mediators (IL-1␤, MPO, IL-10, and IL-19) was increased in colons from wild-type mice following DSS treatment and was not further increased in the absence of TFF2 (Fig. 4B) . Finally, we measured expression of IL-33, which can have damaging and protective effects in colitis, depending on the circumstances and extent of its expression (9, 14, 40) . Moreover, in the lung, expression of IL-33 has been shown to be positively regulated by TFF2 (56) . Consistent with this finding, in DSSinduced colitis, expression of IL-33 mRNA was increased in wild-type, but not TFF2-deficient, mice ( It has been reported that macrophages lacking TFF2 are hyperresponsive to stimulation (23) . Here peritoneal exudative macrophages were isolated from wild-type and TFF2-deficient mice and stimulated in vitro with LPS. Unstimulated macrophages from TFF2-deficient mice appeared to be hypoactivated, with reduced expression of IL-6, IL-1␤, IL-10, IL-19, and IL-33 relative to macrophages from wild-type mice (Fig.  4C ). After stimulation with LPS, macrophages from TFF2-deficient mice are more capable of stimulating an inflammatory response, as they express increased levels of proinflammatory IL-6 and IL-1␤ and, correspondingly, reduced levels of antiinflammatory IL-10 and IL-19, compared with wild-type cells (Fig. 4C) . As observed in the colon, isolated macrophages from TFF2-deficient mice express reduced levels of IL-33, basally and with LPS stimulation (Fig. 4C) . These data corroborate the previously published report that macrophages from TFF2-deficient mice are hyperresponsive; however, this is the first demonstration of altered expression of IL-33 and IL-19 in TFF2-deficient macrophages, and changes in expression of these cytokines have been implicated in susceptibility to colitis (2, 6, 14) . However, this does not translate into increased DSS-induced colonic damage indexes of TFF2-deficient mice compared with wild-type mice in this acute model.
TFF2 deficiency promotes recruitment of inflammatory cells in DSS-induced colitis.
Inflammatory cells were isolated from two regions of the colons of wild-type and TFF2-deficient mice subjected to the acute (8- (Fig. 5) . Inflammation was more pronounced in the DSS-treated TFF2-deficient than wildtype mice, with moderately increased numbers of Th cells in the IELs and LPMCs and increased numbers of macrophages and dendritic cells in the LPMCs (Fig. 5) . These results support the notion that TFF2 has anti-inflammatory activity, as a deficiency in TFF2 caused a modestly elevated inflammatory response following DSS treatment. However, as previously noted, slightly elevated inflammation did not translate into increased colonic damage indexes in this acute model.
TFF2 expression by bone marrow-derived cells does not compensate for TFF2 deficiency in DSS-induced colitis
susceptibility. TFF2-deficient mice were lethally irradiated and transplanted with bone marrow derived from wild-type or TFF2-deficient donor mice. Transplanted mice were left for 8 wk to allow for complete repopulation of the immune system and then subjected to the acute DSS protocol. Reconstitution of the immune system was verified by PCR analysis. Spleens of mice transplanted with bone marrow from TFF2-deficient mice contained mRNA only for the TFF2 mutant allele, and spleens of mice transplanted with bone marrow from wild-type mice contained mRNA for the wild-type and the TFF2 mutant allele (Fig. 6A) . Additionally, fluorescence-activated cell sorting analysis of the blood of the recipient animals at the time of culling showed numbers of leukocytes that were normal and in the correct proportions in all animals. No differences were noted between mice that received a transplant from TFF2-deficient mice and those that received a transplant from wildtype mice (data not shown).
After acute (8-day) DSS colitis induction, TFF2-deficient mice that received a bone marrow transplant lost the same amount of weight as the nontransplanted TFF2-deficient mice, regardless of whether they were transplanted with bone marrow from wild-type or TFF2-deficient mice (Fig. 6Bi) . The extent of colonic damage following DSS treatment was also not affected by TFF2 expression in bone marrow-derived cells (Fig. 6Bii ).
An incidental finding throughout all these experiments is a significantly greater weight loss in the TFF2-deficient watertreated control than wild-type mice. This result was consistent, regardless of other interventions, including bone marrow transplantation (Fig. 6C ). Also consistent with this subtle, but consistent, weight loss in TFF2-deficient water-treated controls, was a decrease in TFF3 expression in the colons of TFF2-deficient mice (Ϫ1.78 Ϯ 0.15 fold; Fig. 1 ) and a small increase in expression of inflammatory mediators [IL-19 (5.61 Ϯ 3.24 fold), IL-33 (2.01 Ϯ 0.24 fold), and MPO (1.83 Ϯ 0.15 fold); Fig. 4B ]. These changes in mRNA did not reach statistical significance, but the fact that they are all trending upward in conjunction with the increased weight loss suggests low-level basal inflammation coincident with some weight loss over the course of the experiment in colons of the TFF2-deficient mice.
To further evaluate the outcome of TFF2-deficient or -replete bone marrow transplantation, relevant cytokine mRNA from the colitic colon of bone marrow-transplanted mice was quantified. Expression of IL-6 and MPO was increased in TFF2-deficient mice transplanted with bone marrow from TFF2-deficient mice following acute DSS treatment and further augmented in mice transplanted with bone marrow from wild-type mice [ Fig. 7 ; IL-6 (103.7 Ϯ 23.1 and 455.7 Ϯ 132.8 fold) and MPO (1.6 Ϯ 0.58 and 6.5 Ϯ 1.1 fold)]. However, expression of other inflammatory moderators such as IL-1␤, which was increased in colons of TFF2-deficient mice transplanted with bone marrow from TFF2-deficient mice following DSS treatment, was not further increased in mice transplanted with bone marrow from wild-type mice (Fig. 7) . This finding demonstrates that TFF2 deficiency in bone marrow-derived cells causes an attenuated, not exaggerated, inflammatory response in the DSS-treated colon in this acute model. Our data further support the notion that TFF2 deficiency in bone marrow-derived cells is not essential for driving increased susceptibility of TFF2-deficient mice to acute DSS-induced colitis.
DISCUSSION
TFF2 is a key regulatory factor secreted by the gastrointestinal epithelium. While TFF2-deficient mice maintained in low-pathogen conditions have a comparatively mild gastric pathology, deficiency of TFF2 in the stomach dramatically exacerbates the severity of Helicobacter pylori infection and accelerates gastric tumorigenesis in mouse models (34) . Similarly, we demonstrate here that, in acute and chronic models of DSS colitis, TFF2 deficiency potentiates weight loss associated with susceptibility to colonic inflammation. The mechanism by which DSS induces colitis is most likely multimodal but primarily represents a damage-induced model of injury and repair. DSS is directly toxic to the colonic epithelium and, therefore, compromises the intestinal barrier and increases the permeability of the tissue (33) . This is evidenced by the resistance of germ-free or antibiotic-treated mice to DSSinduced pathologies. The susceptibility to DSS-induced colitis can be manipulated by further alteration of the intestinal barrier function or the immune response following compromise to the barrier (45) . The TFFs, in particular TFF2, are known to have important roles in the maintenance of epithelial barrier function and repair and restitution of mucosal surfaces, as well as in modulation of the immune response over the long term, thus underscoring the importance of TFF2 in ameliorating colitis. Here we show that, in the colon, TFF2 is preferentially expressed by the epithelial cells, which is crucial for maintenance of body weight during DSS-induced colitis but has no effect on colonic shortening or ulceration. This suggests that TFF2 is required to maintain barrier function and likely limits dehydration from the colon upon insult but does not influence damage to the colon response per se.
An important finding of the current study is that expression of the main colonic trefoil TFF3 is regulated by TFF2 in colonic and immune tissues. Colonic TFF3 expression is strongly inhibited after deletion of the TFF2 gene, suggesting that TFF2 normally promotes TFF3 colonic expression, thereby contributing to enhanced barrier function. This may be a key local regulatory role for TFF2. Colonic TFF3 deficiency leads . TFF2 deficiency alters recruitment of inflammatory cells to colonic mucosa. Wild-type (n ϭ 7) and TFF2-deficient (n ϭ 7) mice were subjected to the acute DSS protocol, colons were harvested, and inflammatory cells were isolated. The 2 cell populations derived from the isolation, intraepithelial leukocytes and lamina propria mononuclear leukocytes, were stained with the antibodies CD4, CD8␣, CD11b, CD11c, CD45R, and Ly6G/C and analyzed by fluorescence-activated cell sorting with CountBright beads to determine the number of different leukocyte populations in the DSS-treated colon.
to increased severity of radiotherapy-or chemotherapy-induced mucositis (3), chemically induced colitis due to impaired mucosal repair (28, 36) , and reduced resistance to damageinduced apoptosis (48) . On the other hand, thymic and, to a lesser extent, splenic TFF3 is induced in the absence of the TFF2 gene, implying that TFF2 normally represses TFF3 expression in these organs. TFF3 has previously been identified as an intrathymic medullary antigen that can be upregulated by the autoimmune regulatory gene Aire (22) , suggesting that its role in the thymus is to instruct the T cell repertoire of Fig. 6 . Bone marrow-derived cells expressing TFF2 do not alter susceptibility of TFF2-deficient mice to DSS-induced colitis. A: contribution of bone marrow-derived cells to DSS susceptibility was assessed by production of bone marrow chimeras. TFF2-deficient mice were transplanted with bone marrow from wild-type or TFF2-deficient mice (both n ϭ 9) and, after complete reconstitution, subjected to the acute DSS protocol. Analysis of splenic mRNA from these mice demonstrated that those that received the bone marrow from TFF2-deficient mice expressed only mutant TFF2, while those that received bone marrow from wild-type mice expressed wild-type and mutant TFF2. B: weight (i) and colon damage (ii) demonstrate that TFF2-expressing bone marrow-derived cells are unable to protect the TFF2-deficient mouse from increased susceptibility to DSS-induced colitis. C: control TFF2-deficient mice (n ϭ 7) that received water only lost significantly more weight than their wild-type counterparts (n ϭ 7). *P Յ 0.05 vs. all TFF2-deficient mice, regardless of transplant status. extrathymic self-antigens. As TFF2 is also expressed in the thymus and expression of TFF3 in the spleen and thymus appears to be similarly regulated by TFF2, further analysis of the actions of TFF2 and TFF3 on lymphocyte development and migration to lymph nodes and the gut mucosa is warranted. It is also possible that key TFF3 regulatory elements are located within the TFF2 locus and that deletion of these elements (in the TFF2 knockout mice) leads to the alterations in TFF3 expression. This seems unlikely, however, because TFF3 expression is suppressed in the colon, but stimulated in spleen and thymus, of TFF2-deficient mice.
TFF2 has been traditionally viewed as an exclusively stomach protein, albeit with expression in the colon associated with colitis induction. We first showed that TFF2 was expressed by rat lymphoid tissues outside the gut, including the spleen and the thymus, most likely in macrophages in the former (7), raising the prospect that TFF2 may have immunomodulatory activity. These observations have been extended by Kurt-Jones et al. (23) , who showed that TFF2 deficiency markedly increased the IL-1␤ responsiveness of mouse macrophages but that LPS sensitivity was not different from wild-type cells. Conversely, we demonstrate here that peritoneal macrophages from TFF2-deficient mice are hyperresponsive to LPS stimulation, showing elevated levels of IL-6 and IL-1␤ and reduced levels of IL-10 and IL-19, a pattern of cytokine expression that matches that of the colon during DSS-induced colitis. This difference may be explained in part by the differing genetic backgrounds of the mice in each study: cells from mixedlineage TFF2-deficient (C57BL/6 ϫ 129Sv) mice were used by Kurt-Jones et al., while the mice used in the current study were backcrossed more than eight generations onto C57BL/6. Additionally, we demonstrate here that TFF2 expression in the spleen is strongly induced by variable environmental stimuli, and we would therefore predict that peritoneal macrophages sourced from different laboratories may behave differently in vitro.
Although epithelial mucous cells and immunocytes express TFF2, in the colon it appears that TFF2 is expressed by epithelial cells, rather than leukocytes. Bone marrow transfer experiments show that TFF2-deficient mice transplanted with bone marrow from wild-type or TFF2-deficient mice were equally susceptible to weight loss after DSS-induced colitis at early time points (day 8). This suggests that neither resident nor infiltrating leukocyte-derived TFF2 contributes substantially to the resistance to acute DSS-induced colitis, which is consistent with this epithelial damage model. Therefore, it seems likely that epithelial TFF2, produced in the stomach and secreted luminally or from the colon or both, carries out this function. Both sources are plausible, since secreted TFF2, by virtue of its disulfide-bound tertiary structure, is highly stable in gastric juice.
There are several caveats and limitations to our conclusions. First, most of our analysis was done after short-term (8 days) follow-up, so potentially important, but more slowly developing, immunomodulatory effects of TFF2 may not have been detected. Second, while our previous dosing experiments (4) and the results presented here appear to point to a luminal role for TFF2, other studies (1, 53; T. C. Wang et al., unpublished data) have shown that TFF2 is also secreted, presumably mainly from the gastric epithelium, into the circulation, where it can mediate systemic effects, including effects on the immune system. This would be consistent with earlier reports that have shown that parenteral administration of trefoil peptides can also mediate resistance to colitis and gastric injury (21, 35) . Thus the recognition that the gastric (probably supplemented by the colonic) epithelium is indeed the primary source of TFF2 does not preclude the possibility of a luminal or a circulatory mode of action. Future resolution of this issue will require epithelial-specific deletion of TFF2 in gastric and colonic mucosae or overexpression of TFF2 in the hematopoietic system, with acute and chronic DSS challenge, and is outside the scope of the present study. Additionally, intrarectal administration of TFF2 or TFF3 (if available) to TFF2-deficient mice with DSS-induced colitis would assist in demonstrating the therapeutic potential of these peptides in inflammatory bowel disease and, additionally, demonstrate if luminal trefoils alone are sufficient to modify pathologies generated by DSS-induced colitis.
The cytokine IL-33 has recently been described as an alarmin in epithelial tissues, the function of which is to mobilize the innate immune system in the very early stages of epithelial tissue damage to initiate inflammatory and repair processes (26, 30, 31, 41) . In the lung, expression of IL-33 is dependent on TFF2 (56). Here we show a similar interdependence between TFF2 and IL-33 expression in the colon and in peritoneal macrophages. The role of IL-33 in colitis is controversial, being very dependent on the timing of its activation or expression relative to the damaging insult. Exogenous IL-33 administered simultaneously with DSS leads to exacerbation of DSS-induced colitis; when administered after DSS, however, IL-33 can lead to improved recovery (9, 14) and reduced goblet cell loss (17) . IL-33-deficient mice showed increased weight loss with DSS-induced colitis but, surprisingly, also showed increased survival rates (30, 39) . We found that colonic IL-33 mRNA increased with DSS-induced colitis and that this increase was dependent on TFF2. The possibility remains that the attenuated IL-33 response in TFF2-deficient mice partly contributes to the DSS-induced phenotype.
In this study we have confirmed that TFF2-deficient, but not TFF1-deficient, mice have increased susceptibility to DSSinduced colitis. In contrast to earlier suggestions, the increased susceptibility to acute (8 days) DSS-induced colitis is not primarily due to expression of TFF2 in leukocytes. Our data support the possibility that TFF2 regulates expression of TFF3 and IL-33 in the colonic epithelium, and, therefore, TFF2-deficient colons have compromised barrier function and Th2 immune responses, resulting in increased susceptibility to DSS-induced colitis. The significance of direct TFF2 modulation of the immune response is still not entirely apparent and requires further investigation. 
